ArticleThe American journal of pathology2016
Galectin-3, Cardiac Function, and Fibrosis.
Article in The American journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Myocardial Fibrosis in Cardiovascular Disease: An Integrative Biomarker-Imaging Framework Linking Molecular Mechanisms to Structural Phenotypes.Journal of clinical medicine · 2026Review
- Galectin-3 inhibition ameliorates hepatic steatosis in a multilineage 3D spheroid model.PloS one · 2025Article
- Glycopolymer Inhibitors of Galectin-3 Suppress the Markers of Tissue Remodeling in Pulmonary Hypertension.Journal of medicinal chemistry · 2024Article
- Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure.Biomolecules · 2023Article
- Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC).European journal of heart failure · 2021Review
- Trypanosoma cruzi cleaves galectin-3 N-terminal domain to suppress its innate microbicidal activity.Clinical and experimental immunology · 2020Article
- Stimulation of β-adrenoceptors up-regulates cardiac expression of galectin-3 and BIM through the Hippo signalling pathway.British journal of pharmacology · 2019Article
- Moving galectin-3 closer to the goal line.American journal of physiology. Heart and circulatory physiology · 2019Article
- Intermediate filaments in cardiomyopathy.Biophysical reviews · 2018Review
- Cystatin C and galectin-3 as therapeutic targets in heart failure.Therapeutic advances in cardiovascular disease · 2018Article
- Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).International journal of molecular medicine · 2018Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This Correspondence relates to the article by Frunza et al (Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis. Am J Pathol 2016, 186:1114-1127).
Indexed as
Identifiers
27461364What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.